An analysis of data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) identified distinct patterns of response in patients with RA who began anti-TNF treatment between 2001 and 2013. The trajectories of treatment response were apparent within a few months of treatment initiation and reflected long-term outcomes. In a four-class model, most patients in the study followed a ‘modest’ (55.3%) or ‘substantial’ (32.4%) response trajectory, with 8.7% of the patients fitting the ‘maximal’ response trajectory (corresponding to sustained remission) and 3.6% the ‘minimal’ response trajectory.